Pharming Technologies
As of the edition of 20 October 2026, Pharming Technologies runs 3 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 1 target.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Conestat alfa | Ended 2026 (reference-product exclusivity) | 0 |
| Leniolisib | Ends 2032 (patent) | 1 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 1 target.
| Target | Route |
|---|---|
| PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Route B |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Pharming Technologies needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 6 trials led
- Inherited and neonatal: 4 trials led
- Heart and blood vessels: 3 trials led